Radiation Oncology

Radiation therapy uses high-energy radiation to damage cancer cells' DNA and destroy their ability to divide and grow. It is delivered using linear accelerators, proton accelerators, metered cobalt-60 exposure, or brachytherapy where radioactive seeds are placed inside the patient on a temporary or permanent basis to kill cancer or relieve pain. The main radiation oncology society and annual conference is the American Society of Radiation Oncology (ASTRO).

Lantheus receives tentative FDA approval for its radio-equivalent to Lutathera
Lantheus’ version of a radiopharmaceutical capable of targeting somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been tentatively approved by the FDA.
Novartis building massive new radioligand manufacturing facility as part of $23B investment in US
The 46,000 square foot Denton site will be the fifth Novartis has constructed stateside. The company expects it to be fully operational by 2028.
Radiopharmaceutical targeted toward treatment-resistant cancer put on FDA's Fast Track
The treatment addresses cancers that express Nectin-4, a protein found in excess of 80% to 90% of urothelial cancer patients.
TAVR a safe treatment option for patients who have undergone chest radiation therapy
In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.
ASTRO launches new training program to expand radiopharmaceutical therapy access
The program creates a network of accredited sites where radiation oncologists can complete the final regulatory requirements needed to become authorized users for RPT.

Lantheus receives tentative FDA approval for its radio-equivalent to Lutathera

Lantheus’ version of a radiopharmaceutical capable of targeting somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been tentatively approved by the FDA.

Novartis building massive new radioligand manufacturing facility as part of $23B investment in US

The 46,000 square foot Denton site will be the fifth Novartis has constructed stateside. The company expects it to be fully operational by 2028.

Radiopharmaceutical targeted toward treatment-resistant cancer put on FDA's Fast Track

The treatment addresses cancers that express Nectin-4, a protein found in excess of 80% to 90% of urothelial cancer patients.

TAVR a safe treatment option for patients who have undergone chest radiation therapy

In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.

ASTRO launches new training program to expand radiopharmaceutical therapy access

The program creates a network of accredited sites where radiation oncologists can complete the final regulatory requirements needed to become authorized users for RPT.

Telix and Siemens Healthineers partner to advance oncologic therapies

Leaders from both companies are optimistic about how their partnership can improve precision medicine and palliative therapies.

Routine IR procedure could treat endometriosis.

ASTRO releases new radiation therapy guidelines for gastric cancers

Many forms of the disease are identified at later stages, making treatment and management complex and multifaceted.

Industry partnership seeks to bolster supply of radioisotopes

Two key companies shared the news Oct. 14, highlighting the potential their partnership has for improving oncologic care.